Ironing out the cross talk between FGF23 and inflammation

Valentin David, Connor Francis, Jodie L. Babitt*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations

Abstract

The bone-secreted hormone fibroblast growth factor 23 (FGF23) has an essential role in phosphate homeostasis by regulating expression of the kidney proximal tubule sodium-phosphate cotransporters as well as parathyroid hormone levels. Induction of FGF23 early in chronic kidney disease (CKD) helps to maintain normal phosphorous levels. However, high FGF23 levels become pathological as kidney disease progresses and are associated with an increased risk of CKD progression, cardiovascular events, and death. The factors responsible for increasing FGF23 levels early in CKD are unknown, but recent work has proposed a role for inflammation and disordered iron homeostasis. Notably, FGF23 has recently been shown to elicit an inflammatory response and to display immunomodulatory properties. Here, we will review emerging evidence on the cross talk between inflammation, iron, FGF23, and bone and mineral metabolism and discuss the relevance for CKD patients.

Original languageEnglish (US)
Pages (from-to)F1-F8
JournalAmerican Journal of Physiology - Renal Physiology
Volume312
Issue number1
DOIs
StatePublished - 2017

Keywords

  • Chronic kidney disease
  • Fibroblast growth factor 23
  • Iron
  • Mineral metabolism

ASJC Scopus subject areas

  • Physiology
  • Urology

Fingerprint Dive into the research topics of 'Ironing out the cross talk between FGF23 and inflammation'. Together they form a unique fingerprint.

Cite this